Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2004-08-12
2010-02-23
Shiao, Rei-tsang (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
07666885
ABSTRACT:
Compounds of general formula (I):where A, E, G, X, Y and the bond - - - take various meanings are of use in the preparation of a pharmaceutical formulation, for example in the treatment of a disease in which GSK-3 is involved, including Alzheimer's disease or the non-dependent insulin diabetes mellitus, or hyperproliferative disease such as cancer, displasias or metaplasias of tissue, psoriasis, arteriosclerosis or restenosis.
REFERENCES:
patent: 2863803 (1958-12-01), Benghiat et al.
patent: 3374240 (1968-03-01), Ottman et al.
patent: 3534057 (1970-10-01), Krenzer
patent: 3900485 (1975-08-01), Krenzer
patent: 4183816 (1980-01-01), Gavin et al.
patent: 6872737 (2005-03-01), Gil et al.
patent: 7265259 (2007-09-01), Perez et al.
patent: 7531561 (2009-05-01), Padilla et al.
patent: 2005/0222220 (2005-10-01), Padilla et al.
patent: 2109755 (1972-09-01), None
patent: 4420522 (1995-12-01), None
patent: 0 711 773 (1996-05-01), None
patent: 04075997.9 (2004-04-01), None
patent: 1115350 (1968-05-01), None
patent: 58216177 (1983-12-01), None
patent: WO 95/17182 (1995-06-01), None
patent: WO 00/21927 (2000-04-01), None
patent: WO 00/38675 (2000-07-01), None
patent: WO 01/09106 (2001-02-01), None
Martinez et al., “Synthesis and Potential Muscarinic Receptor Binding and Antioxidant Properties of 3-(Thiadiazolyl)pyridine 1-Oxide Compounds”Arch. Pharm. Pharm. Med. Chem., vol. 332, pp. 191-194 (1999).
Slomczynska et al., “Efficient Synthesis of 1,2,4—Dithiazolidine-3,5-diones (Dithiasuccinoyl-amines) and Observation on Formation of 1,2,4—Thiadiazolidine-3,5-diones by Related Chemistry”,J. Heterocyclic Chem., vol. 21, pp. 241-246 (1984).
STN Registry No. 89570-37-6.
Eghtessad et al., “Uber die Reaktion von Benzylisothiocyanat mit Glyoxal-di(tert-butylnitron)”, Arch. Pharm. (Weinheim) 373, 357-361, 1980, Abstract.
Bao et al., “Glycogen Synthase Kinase-3β Inhibition Attenuates Asthma in Mice”, AJRCCM Articles in Press, published Jun. 7, 2007 as dio:10.1164/rccm.200609-1292OC.
Collino et al., “Treatment with Glycogen Synthase Kinase-3β Inhibitor, TDZD-8, Affects Transient Cerebral Ishemia/Reperfusion Injury in the Rat Hippocampus”, Shock, 2008, pp. 1-10.
Cuzzocrea et al., “Glycogen Synthase Kinase-3β Inhibition Reduces Secondary Damage in Experimental Spinal Cord Trauma”, JPET Fast Forward, published on Apr. 6, 2006 as DOI:10.1124/jpet.106.102863.
Cuzzocrea et al., “Effects of Glycogen Synthase Kinase-3β Inhibition on the Decelopement of Cerulein-Induced acute Pancreatitis in Mice”, Crit. Care Med, 2007, vol. 35, vol. 12, pp. 2811-2821.
Cuzzocrea et al., “Glycogen Synthase Kinase-3β Inhibition Attenuates the Degree of Arthritis Caused by Type II Collagen in the Mouse”, Elsevier, Critical Immunology, 2006, pp. 1-11.
Cuzzocrea et al., “Glycogen Synthase Kinase-3β Inhibition Attenuates the Development of Ischaemia/Reperfusion Injury of the Gut”, Intensive Care Med., 2007, pp. 1-14.
Cuzzocrea et al., “Glycogen Synthase Kinase-3β Inhibition Attenuates the Development of Bleomycin-Induces Lung Injury”, International Journal of Immunopathology and Pharmacology, 2007, vol. 20, No. 3, pp. 619-630.
Cuzzocrea et al., “Inhibition of Glycogen Synthase Kinase-3β Attenuates the Development of Carrageenan-Induced Lung Injury in Mice”, British Journal of Pharmacology, 2006, pp. 1-16.
Dugo et al., “Insulin Reduces the Multiple Organ Injury and Dysfunction Caused by Coadministration of Lipolysaccharide and Peptidoglycan Independently of Blood Glucose: Role of Glycogen Synthase Kinase-3β Inhibition”, Crit Care Med, 2006, vol. 34, No. 5, pp. 1-8.
Dugo et al., “Glycogen Synthase Kinase-3β as a Target for Therapy of Shock and Inflammation”, Shock, 2007, vol. 27, No. 2, pp. 113-123.
Farago et al., “Kinase-Inactive Glycogen Syntahse Kinase-3β Promotes Wnt Signaling and Mammary Tumorigenesis”, Cancer Res., 2005, vol. 65, No. 13, pp. 5792-5801.
Ghosh et al., Activation of p53-Dependent Apoptosis by Acute Ablation of Glycogen Synthase Kinase-3β in Colorectal Cancer Cells:, CLin Cancer Res, 2005, vol. 11, No. 12, pp. 4580-4588.
Guzman et al., “Rapid and Selective Death of Leukemia Stem and Progenitor Cells induced by the Compound 4-benzyl, 2-methyl, 1,2,4-thiadiazolidine, 3,5 dione (TDZD-8)”, Blood, 2007, vol. 110, No. 13, pp. 4436-4444.
Jordan, Craig T., “The Leukemic Stem Cell”, Best Practice & Research Clinical Haematology, 2007, vol. 20, No. 1, pp. 13-18.
Sun et al., “Lithium Suppresses Cell Proliferation by Interrupting E2F-DNA Interaction and Subsequently Reducing S-Phase Gene Expression in Prostate Cancer”, The Prostate, 2007, vol. 67, pp. 976-988.
Whittle et al., Reduction of Experimental Colitis in the Rat by Inhibitors of Glycogen Synthase Kinase-3β, British Journal of Pharmacology, 2005, pp. 1-8.
Andricopulo et al., “Structure-Activity Relationships for the Design of Small-Molecule Inhibitors”, Mim-Reviews in Medicinal Chemistry, 2005, vol. 5, 585-593.
Aoukaty et al., “Role for Glycogen Synthase Kinase-3 in NK Cell Cytotoxicity and X-Linked Lymphoproliferative Disease”, The Journal of Immunology, 2005, pp. 4551-4558.
Barry et al., “Regulation of glycogen synthase kinase 3 in human platelets: a possible role in platelet function?”, FEBS Letters, 2003, vol. 553, pp. 173-178.
Caricasole et al., “Induction of Dickkopf-1, a Negative Modulator of the Wnt Pathway, Is Associated with Neuronal Degeneration in Alzheimer's Brain”, The Journal of Neuroscience, 2004, vol. 24, No. 26, pp. 6027-6021.
Chen et al., “Glycogen synthase kinase 3β (GSK3β) mediates 6-hydroxydopamine-induced neuronal death”, The FASEB Journal express article 10.1096/fj.04-1551fje—published online May 7, 2004.
Chin et al., “Inhibition of GSK3β is a common event in neuroprotection by different survival factors”, Molecular Brain Research, 2005, vol. 137, pp. 193-201.
Collino et al., “Treatment with the Glycogen Synthase Kinase-3β Inhibitor, TDZD-8, affects transient cerebral ischemia/reperfusion injury in the rat hippocampus”, Shock Society, 2008, pp. 1-10.
Cuzzocrea et al., “Glycogen synthase kinase kinase-3β inhibition attenuates the degree of arthritis caused by type II collagen in the mouse”, Clinical Immunology, 2006, pp. 1-11.
Cuzzocrea et al., “Glycogen synthase kinase-3β inhibition reduces the development of nonseptic shock induced by zymosan in mice”, Shock Society, 2006, pp. 1-13.
Cuzzocrea et al., “Glycogen synthase kinase-3β inhibition reduced secondary damage in experimental spinal cord trauma”, JPET Fast Forward, published on Apr. 6, 2006 as DOI:10.1124/jpet.102863, pp. 1-46.
Cuzzocrea et al., “Inhibition of glycogen synthase kinase-3β attenuates the development of carrageenan-induced lung injury in mice”, British Journal of Pharmacology, 2006, pp. 1-16.
Ding et al., “Degradation of Mc1-1 by β-TrCP Mediates Glycogen Synthase Kinase 3-Induced Tumor Suppression and Chemosensitization”, Molecular and Cellular Biology, 2007, pp. 4006-4017.
Dugo et al., “Glycogen synthase kinase-3β inhibitors protection against the organ injury and dysfunction caused hemorrhage and resuscitation”, Shock, 2006, vol. 25, No. 5, pp. 485-491.
Dugo et al., GSK-3β inhibitors attenuate the organ injury/dysfunction caused by endotoxemia in the rat, Crit. Care Med., 2005, vol. 33, No. 9, pp. 1903-1912.
Dugo et al., “Insulin reduces the multiple organ injury and dysfunction caused by coadministration of lipopolysaccharide and peptidoglycan independently of blood glucose: Role of glycogen synthase kinase-3β inhibition”, Crit. Care Med., 2006, vol. 24, No. 5, pp. 1.
Engel et al
Cascon Mercedes Alonso
Diaz Isabel Dorronsoro
Jurado Francisco Wandosell
Martin Perez Maria Concepcion
Martinez Ana Gil
Consejo Superior de Investigaciones Cientificas
Fish & Richardson P.C.
Shiao Rei-tsang
Universidad Autonoma de Madrid (UAM)
LandOfFree
Enzyme inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Enzyme inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Enzyme inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4164347